9:00am Chair Introduction

Ana Rosa Sáez Ibáñez, Research Analyst, Cancer Research Institute 

9:05am Presentation: NK Cells Impacting Oncology Pipelines

• Off-the-shelf is a minmum
• Potency is crucial

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics

9:20am Presentation: The Innovator’s Dilemma for Cancer Therapies: Going from ‘Novel’ to ‘Disruptive’

• Most advanced therapies are novel, but not yet disruptive in the marketplace.
• Disruptive innovation requires success across the clinical value chain from cross-disciplinary teams.
• Once we become disruptive, how do we stay disruptive?

Anne Cox, Director of Business Development, Tensentric

9:35am Presentation: Overcoming the Misconception of CAR-T’s for Solid Tumors

• CAR-T Signaling Refinements designed for Solid tumors
• Evidence of Early Success
• The Luminary Approach
• An allogeneic manufacturing chassis for Solid Tumors

Jeff Liter, Chief Executive Officer, Luminary Therapeutics

9:50am Presentation: Scalable Manufacture of CAR-NK Cells from Engineered Pluripotent Stem Cells with 3-D Bioreactor

• A proprietary scalable 3D iPS-NK manufacture platform with defined, serum-free and feeder-free conditions: pure and strong functional iPS-NK with CD8+ effector cell identity for immunotherapy

• Establishment of permanent, stable, genetically-engineered and clonal iPS-CAR lines for the manufacture of unlimited homogenous CAR-NK cells from multiple master iPS-CAR cell banks
• Development of next-generation 3D bioreactor platform and logistics: the ultimate goal of making CAR-NK products affordable and available for ordinary patient

Allen Feng, Chief Scientific Officer, HebeCell

10:05am Closing Panel with Q&A

With all session participants